Nuvation Bio stock kpis
Want to see NUVB full AI Analyst Report?
Revenue by Type
Nuvation Bio reported revenue by type of $31.69M in Q2 2026, down 61.9% from Q1 2026 and up 555.6% year over year. The highest value was $83.23M in Q1 2026.
Breaks down revenue into sources such as product sales, licensing, collaboration and milestone payments, and grants, highlighting whether income is recurring or one-time. For clinical-stage Nuvation Bio, which likely has limited commercial sales, this reveals reliance on partnerships and milestone receipts to fund R&D, the timing risks to cash flow and runway, and how close the company is to generating steady product revenue.
Product revenue has moved from zero to a meaningful ramp driven by Iptrozy's growing first‑line share and sequential unit growth, but the recent quarter’s surge was predominantly an Eisai upfront in collaboration revenue—underscoring lumpiness and milestone dependence. Sustainable, non‑volatile net revenue hinges on expanding new patient starts and testing adoption and maintaining first‑line penetration while GTN normalizes and hefty operating spend continues; management’s cash cushion lowers financing risk, though milestone timing keeps near‑term quarters volatile.
NUVB Revenue by Type
| Period | Product | Collaboration & License Agreements | Total |
|---|---|---|---|
| Q2 2026Jun 30, 2026 | $23.19M | $8.49M | $31.69M |
| Q1 2026Mar 31, 2026 | $18.51M | $64.72M | $83.23M |
| Q4 2025Dec 31, 2025 | $15.70M | $26.16M | $41.87M |
| Q3 2025Sep 30, 2025 | $7.72M | $5.40M | $13.12M |
| Q2 2025Jun 30, 2025 | $1.24M | $3.60M | $4.83M |
| Q1 2025Mar 31, 2025 | $0.00 | $3.08M | $3.08M |
| Q4 2024Dec 31, 2024 | $0.00 | $5.71M | $5.71M |
| Q3 2024Sep 30, 2024 | $0.00 | $727.00K | $727.00K |
| Q2 2024Jun 30, 2024 | $0.00 | $1.44M | $1.44M |
| Q1 2024Mar 31, 2024 | $0.00 | $0.00 | $0.00 |

